A Network Pharmacology Approach to Explore the Mechanism of HuangZhi YiShen Capsule for Treatment of Diabetic Kidney Disease

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2021 Sep 9

PMID 34497749

Citations 9

Authors

Xue-Feng Zhou

Wei-E Zhou

Wen-Jing Liu

Min-Jing Luo

Xia-Qing Wu

Ying Wang

Peng Liu

Yu-Min Wen

Jia-Lin Li

Ting-Ting Zhao

Hao-Jun Zhang

Hai-Ling Zhao

Ping Li

Affiliations

Soon will be listed here.

Abstract

Background And Objective: HuangZhi YiShen Capsule (HZYS) is a Chinese patent herbal drug that protects kidney function in diabetic kidney disease (DKD) patients. However, the pharmacologic mechanisms of HZYS remain unclear. This study would use network pharmacology to explore the pharmacologic mechanisms of HZYS.

Methods: Chemical constituents of HZYS were obtained through the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and literature search. Potential targets of HZYS were identified by using the TCMSP and the SwissTarget Prediction databases. DKD-related target genes were collected by using the Online Mendelian Inheritance in Man, Therapeutic Target Database, GeneCards, DisGeNET, and Drugbank databases. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were carried out to further explore the mechanisms of HZYS in treating DKD. Molecular docking was conducted to verify the potential interactions between the prime compounds and the hub genes.

Results: 179 active compounds and 620 target genes were obtained, and 571 common targets were considered potential therapeutic targets. The top 10 main active compounds of HZYS were heparin, quercetin, kaempferol, luteolin, methyl14-methylpentadecanoate, methyl (Z)-11-hexadecenoate, 17-hydroxycorticosterone, 4-pregnene-17α, 20β, 21-triol-3, 11-dione, wogonin, and hydroxyecdysone. Hub signaling pathways by which HZYS treating DKD were PI3K-Akt, MAPK, AGE-RAGE in diabetic complications, TNF, and apoptosis. The top 10 target genes associated with these pathways were and . Quercetin and Luteolin were verified to have good binding capability with the hub potential targets through molecular docking.

Conclusion: HZYS appeared to treat DKD by regulating the inflammatory, oxidative stress, apoptotic, and fibrosis signaling pathways. This study provided a novel perspective for further research of HZYS.

Citing Articles

Chemical composition, biological activities, and quality standards of hawthorn leaves used in traditional Chinese medicine: a comprehensive review.

Guo W, Shao T, Peng Y, Wang H, Chen Z, Su H Front Pharmacol. 2023; 14:1275244.

PMID: 37927599 PMC: 10623334. DOI: 10.3389/fphar.2023.1275244.

A Comprehensive Weighted Gene Co-expression Network Analysis Uncovers Potential Targets in Diabetic Kidney Disease.

Pan S, Li Z, Wang Y, Liang L, Liu F, Qiao Y J Transl Int Med. 2023; 10(4):359-368.

PMID: 36860636 PMC: 9969566. DOI: 10.2478/jtim-2022-0053.

Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy.

Mota-Zamorano S, Gonzalez L, Robles N, Valdivielso J, Arevalo-Lorido J, Lopez-Gomez J Ann Med. 2022; 54(1):3039-3051.

PMID: 36314849 PMC: 9635471. DOI: 10.1080/07853890.2022.2138531.

Phosphoproteomics reveals that cinobufotalin promotes intrahepatic cholangiocarcinoma cell apoptosis by activating the ATM/CHK2/p53 signaling pathway.

Xia Z, Li M, Hu M, Lin Y, Atteh L, Fu W Front Oncol. 2022; 12:982961.

PMID: 36185307 PMC: 9523695. DOI: 10.3389/fonc.2022.982961.

Calcium dobesilate efficiency in the treatment of diabetic kidney disease through suppressing MAPK and chemokine signaling pathways based on clinical evaluation and network pharmacology.

Du B, Yin Y, Wang Y, Fu H, Sun H, Yue Z Front Pharmacol. 2022; 13:850167.

PMID: 36160448 PMC: 9493050. DOI: 10.3389/fphar.2022.850167.

References

Zang Y, Zhang L, Igarashi K, Yu C . The anti-obesity and anti-diabetic effects of kaempferol glycosides from unripe soybean leaves in high-fat-diet mice. Food Funct. 2015; 6(3):834-41. DOI: 10.1039/c4fo00844h. View

Park S, Lim W, You S, Song G . Ameliorative effects of luteolin against endometriosis progression in vitro and in vivo. J Nutr Biochem. 2019; 67:161-172. DOI: 10.1016/j.jnutbio.2019.02.006. View

Zhang M, He L, Liu J, Zhou L . Luteolin Attenuates Diabetic Nephropathy through Suppressing Inflammatory Response and Oxidative Stress by Inhibiting STAT3 Pathway. Exp Clin Endocrinol Diabetes. 2020; 129(10):729-739. DOI: 10.1055/a-0998-7985. View

Sharma D, Gondaliya P, Tiwari V, Kalia K . Kaempferol attenuates diabetic nephropathy by inhibiting RhoA/Rho-kinase mediated inflammatory signalling. Biomed Pharmacother. 2018; 109:1610-1619. DOI: 10.1016/j.biopha.2018.10.195. View

Yuan H, Ma Q, Cui H, Liu G, Zhao X, Li W . How Can Synergism of Traditional Medicines Benefit from Network Pharmacology?. Molecules. 2017; 22(7). PMC: 6152294. DOI: 10.3390/molecules22071135. View

Hagiwara S, Sourris K, Ziemann M, Tieqiao W, Mohan M, McClelland A . RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis. Diabetes. 2018; 67(5):960-973. DOI: 10.2337/db17-0538. View

Kim S, Chin Y, Cho J . Protection of Cultured Cortical Neurons by Luteolin against Oxidative Damage through Inhibition of Apoptosis and Induction of Heme Oxygenase-1. Biol Pharm Bull. 2017; 40(3):256-265. DOI: 10.1248/bpb.b16-00579. View

Ru J, Li P, Wang J, Zhou W, Li B, Huang C . TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014; 6:13. PMC: 4001360. DOI: 10.1186/1758-2946-6-13. View

Wishart D, Feunang Y, Guo A, Lo E, Marcu A, Grant J . DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017; 46(D1):D1074-D1082. PMC: 5753335. DOI: 10.1093/nar/gkx1037. View

10.

Che D, Shin J, Kang H, Cho B, Kim Y, Jang S . Luteolin suppresses IL-31 production in IL-33-stimulated mast cells through MAPK and NF-κB signaling pathways. Int Immunopharmacol. 2020; 83:106403. DOI: 10.1016/j.intimp.2020.106403. View

11.

Lu X, Li Y, Li X, Aisa H . Luteolin induces apoptosis through suppressing the MAPK and PI3K signaling pathways in gastric cancer. Oncol Lett. 2017; 14(2):1993-2000. PMC: 5530081. DOI: 10.3892/ol.2017.6380. View

12.

Chen P, Shi Q, Xu X, Wang Y, Chen W, Wang H . Quercetin suppresses NF-κB and MCP-1 expression in a high glucose-induced human mesangial cell proliferation model. Int J Mol Med. 2012; 30(1):119-25. DOI: 10.3892/ijmm.2012.955. View

13.

Mou X, Zhou D, Zhou D, Liu K, Chen L, Liu W . A bioinformatics and network pharmacology approach to the mechanisms of action of Shenxiao decoction for the treatment of diabetic nephropathy. Phytomedicine. 2020; 69:153192. DOI: 10.1016/j.phymed.2020.153192. View

14.

Lei D, Chengcheng L, Xuan Q, Yibing C, Lei W, Hao Y . Quercetin inhibited mesangial cell proliferation of early diabetic nephropathy through the Hippo pathway. Pharmacol Res. 2019; 146:104320. DOI: 10.1016/j.phrs.2019.104320. View

15.

Veglio M, Gruden G, Mormile A, Girotto M, Rossetto P, DEste P . Anticoagulant protein C activity in non-insulin-dependent diabetic patients with normoalbuminuria and microalbuminuria. Acta Diabetol. 1995; 32(2):106-9. DOI: 10.1007/BF00569567. View

16.

Aziz N, Kim M, Cho J . Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol. 2018; 225:342-358. DOI: 10.1016/j.jep.2018.05.019. View

17.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

18.

Du W, An Y, He X, Zhang D, He W . Protection of Kaempferol on Oxidative Stress-Induced Retinal Pigment Epithelial Cell Damage. Oxid Med Cell Longev. 2018; 2018:1610751. PMC: 6280232. DOI: 10.1155/2018/1610751. View

19.

Chen P, Chen J, Zheng Q, Chen W, Wang Y, Xu X . Pioglitazone, extract of compound Danshen dripping pill, and quercetin ameliorate diabetic nephropathy in diabetic rats. J Endocrinol Invest. 2012; 36(6):422-7. DOI: 10.3275/8763. View

20.

Yue S, Liu J, Feng W, Zhang F, Chen J, Xin L . System Pharmacology-Based Dissection of the Synergistic Mechanism of Huangqi and Huanglian for Diabetes Mellitus. Front Pharmacol. 2017; 8:694. PMC: 5633780. DOI: 10.3389/fphar.2017.00694. View